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ABSTRACT: 
AIMS: Relatively little is known about the health outcomes associated with very low plasma 
concentrations of high density lipoprotein cholesterol (HDL-C) mainly because of the small 
numbers of individuals with such extreme values included in clinical trials. We therefore 
investigated the association between low and very low HDL-C concentration at baseline and 
incident all-cause-mortality, death from malignant disease (i.e. cancer), and with fatal or non-
fatal incident coronary heart disease (CHD) in individuals from the Reasons for Geographical 
And Racial Differences in Stroke (REGARDS) study.  
METHODS AND RESULTS: Analysis was based on 21,751 participants from the 
REGARDS study who were free of CHD, other cardiovascular disease and cancer at baseline 
and were categorized by baseline HDL-C into <30 mg/dL (very low), 30 -<40 mg/dL (low), 
and ≥40 mg/dL (reference). A series of incremental Cox proportional hazards models were 
employed to assess the association between the HDL-C categories and outcomes. Statistical 
analysis was performed using both complete case methods and multiple imputations with 
chained equations. After adjustment for age, race and sex, the hazard ratios (HRs) comparing 
the lowest and highest HDL-C categories were 1.48 (95% confidence interval [CI]: 1.28, 1.73) 
for all-cause mortality, 1.35 (95%Cl: 1.03, 1.77) for cancer-specific mortality and 1.39 (95%Cl: 
0.99, 1.96) for incident CHD. These associations became non-significant in models adjusting 
for demographics, cardiovascular risk factors and treatment for dyslipidemia. We found 
evidence for an ‘HDL paradox’ whereby low HDL (30-<40 mg/dL) was associated with 
reduced risk of incident CHD in black participants in a fully-adjusted complete case model 
(HR 0.63; 95%CI: 0.46, 0.88) and after multiple imputation analyses (HR 0.76; 95%CI 0.58, 
0.98). HDL-C (<30 mg/dL) was significantly associated with poorer outcomes in women for 
all outcomes, especially with respect to cancer mortality (HR 2.31; 95%Cl: 1.28, 4.16) in a 
fully-adjusted complete case model, replicated using multiple imputation (HR 1.81; 95%CI 
1.03, 3.20).  
CONCLUSIONS: Low HDL-C was associated with reduced risk of incident CHD in black 
participants suggesting a potential HDL paradox for incident CHD. Very low HDL-C in 
women was significantly associated with cancer mortality in a fully-adjusted complete case 
model.  
Key words: Cholesterol, Coronary Heart Disease, HDL, Malignant Disease, Mortality. 
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INTRODUCTION 
In the 1970s, the Framingham Heart Study (FHS) demonstrated an inverse correlation 
between plasma high density lipoprotein cholesterol (HDL-C) concentrations and coronary 
heart disease (CHD) risk1, an observation that was consistent with previous descriptions of the 
role of HDL in reverse cholesterol transport 2 and which prompted investigations into the 
therapeutic potential of HDL-elevating interventions. Despite early promise 3, recent trials with 
niacin or cholesteryl ester transfer protein (CETP) inhibitors failed to demonstrate that 
treatment to raise HDL-C resulted in improved CV health outcomes4, 5. A study employing 
Mendelian randomization demonstrated that several polymorphisms, which raised HDL-C did 
not reduce the risk of myocardial infarction (MI) 6. Furthermore, it has recently been shown 
that a rare variant of the scavenger receptor B1 is associated with increased HDL-C and an 
increased risk of CHD 7. These data suggest that HDL-C is not implicated in the causal pathway 
of atherosclerosis.  
The accumulation of evidence therefore casts doubt on HDL-elevation as a therapeutic 
strategy. However, the risk conferred by low HDL-C can be ameliorated – a post-hoc analysis 
of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin (JUPITER) trial has shown benefit of statins in this respect 8, 9. Thus, the inverse 
relationship between HDL-C and clinical outcomes necessitates careful study to enable 
identification of patients at risk and to offer risk reduction therapies where they are available. 
While individuals with HDL-C <40 mg/dl are recognized at being increased risk of 
cardiovascular (CV) events, currently relatively little is known about the health outcomes 
associated with very low (<30 mg/dl) HDL-C. Most studies conducted to date have been 
underpowered to detect such differences. One observational study including 43,368 subjects, 
429 of whom had HDL-C <15 mg/dl, showed that most cases of very low HDL-C were 
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associated with secondary causes and that mortality was significantly elevated when HDL-C 
concentrations were <15 mg/dl 10.   
We analyzed data from the REasons for Geographical And Racial Differences in Stroke 
(REGARDS) study to investigate the relationships between low (30 to 39.9 mg/dL) and very 
low (<30 mg/dl) concentrations of HDL-C and CHD incidence, death and all-cause mortality. 
In light of previous observations of inverse relationship between HDL-C and cancer11 we also 
included malignant disease as an endpoint in our analysis. The large size of the cohort and the 
recruitment strategy of the REGARDS study allowed these relationships to be investigated in 
racial subgroups and for comparisons to be made between the sexes. 
 
METHODS 
REGARDS study population 
The REGARDS longitudinal cohort study recruited 30,239 community-dwelling subjects 
between January 2003 and October 2007 12. Participants were selected from commercially 
available lists and recruited through a combination of mail and telephone contact. Because of 
a focus on geographic and racial disparities in stroke mortality, blacks were oversampled 
(44%), as were residents of the southeastern U.S. Stroke Belt states (56%) 12, 13. The Stroke 
Belt states were defined as North Carolina, South Carolina, Georgia, Tennessee, Alabama, 
Mississippi, Arkansas, and Louisiana, with the remaining 44% of the participants selected from 
the remaining 40 contiguous U.S. states 12, 13 
Eligibility criteria included having a name and telephone number in the Gensys database, 
black or white race, English-speaking, aged 45 and older, absence of conditions associated with 
a life expectancy of less than 5 years, living in the community, and not being in or on a waiting 
list for a nursing home. Potential participants with diagnosed malignancy at baseline were 
excluded, those with medical conditions that would preclude long-term participation, and being 
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cognitive impairment as judged by the telephone interviewer 12. The participation rate was 
estimated as 33%, similar to other studies 13 . 
The REGARDS study protocol was approved by the Institutional Review Boards 
governing research in human subjects at the participating centers. All participants provided 
informed consent. 
 
Data collection 
For those agreeing to participate, the telephone interviewers conducted an interview to 
assess cardiovascular disease (CVD) risk factors and medical history. An in-person assessment 
for direct measurement of risk factors (blood pressure, anthropomorphic characteristics, 
electrocardiogram) and collection of blood and urine samples was conducted approximately 2 
to 3 weeks after the telephone interview. Participants (or their surrogates) were contacted by 
telephone at 6-month intervals to detect suspected CVD events and death, with medical records 
associated with suspected events retrieved and adjudicated by a physician panel.  Additionally, 
surveillance for death was performed by use of online sources such as the Social Security Death 
Index and the National Death Index. Cause of death was established by physician review of 
medical history, medical records (when available), interviews with next-of-kin or proxies, 
autopsy reports, death certificates, and the National Death Index. Details of the study design 
are provided elsewhere 12. 
In this analysis, we included REGARDS study participants who fasted overnight prior to 
their study visit, were not missing any explanatory variables of interest, had valid 
measurements of total cholesterol, HDL-C and triglycerides. Because the complete case 
method of analysis has been shown to underestimate risks, especially in black women, we then 
reanalyzed the data, imputing missing values using multiple imputation with chained equations 
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(MICE) 14, 15. REGARDS participants with a history of CHD at baseline were excluded from 
the incident CHD analysis.  
Laboratory assays were conducted as previously described 16. Samples were centrifuged 
an average of 97 min after collection and serum or plasma separated and shipped overnight on 
ice packs to the University of Vermont as previously described17. On arrival, samples were 
centrifuged at 30,000 g at 40C and either analyzed (general chemistries) or stored at below -
800C. C-reactive protein (CRP) was analyzed in batches by particle enhanced 
immunonephelometry using the BNII nephelometer (N High Sensitivity CRP; Dade Behring, 
Deerfield, IL) with interassay coefficients of variation of 2.1-5.7%. Cholesterol, HDL-C, 
triglycerides, and glucose were measured by colorimetric reflectance spectrophotometry using 
the Ortho Vitros Clinical Chemistry System 950IRC instrument (Johnson & Johnson Clinical 
Diagnostics, New Brunswick, NJ) 18. LDL-C was calculated using the Friedewald formula 
from total cholesterol, HDL-C and triglycerides 19 
Demographic factors included participant age, race (black/white) and sex. Measures of 
socio-economic status (SES) included self-reported income level (<$20k, $20k-$34k, $35k-
$74k, ≥$75k) and education level (less than high school, high school graduate, some college, 
college graduate). Alcohol consumption (some, none), physical activity (none, 1-3 times/week, 
4 or more times/week), and current cigarette smoking were assessed during the baseline 
telephone interview. Diabetes was defined as self-reported diabetes medication use or fasting 
glucose ≥126 mg/dL. Body mass index (BMI) (kg/m2) and systolic blood pressure (mmHg) 
were measured during the in-home visit. Albumin-to-creatinine ratio (ACR ≥30 vs <30 mg/g), 
estimated glomerular filtration rate (eGFR) through the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation 20, CRP <1 mg/L, 1-3 mg/L, ≥3 mg/L), low density 
lipoprotein (LDL) and triglycerides were measured through specimens. Use of statins, other 
lipid-lowering medications (fibrates or niacin) and steroids was based on medication inventory. 
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Endpoints 
The three endpoints of interest were: 1) death from any cause, 2) death from malignant 
disease, and, 3) incident fatal or non-fatal CHD, each at or before December 31, 2013 (the last 
date where adjudication of the cause of death was available). The definition of incident CHD 
has been previously described as an incident definite or probable non-fatal MI or CHD death 17. 
MI was classified based on published guidelines and consideration of clinical signs and 
symptoms consistent with ischemia; a rising and/or falling pattern of biomarkers over at least 
6h with a peak at least twice the upper limit of normal; and electrocardiogram (ECG) or other 
imaging findings consistent with ischemia. REGARDS study participants or proxy respondents 
were contacted every 6 months via telephone to assess incident CHD events. Medical records 
were retrieved for adjudication for suspected events. When fatal CHD events were reported, 
interviews with next-of-kin or proxies, medical records in the last year of life, death certificates 
and autopsy reports were examined to determine if a CHD event was the main underlying cause 
of death. Non-fatal MIs and fatal CHD events were adjudicated by trained clinicians following 
published guidelines 21-23. For all analysis of incident CHD, those participants with baseline 
CHD (self-reported MI, coronary artery bypass grafting, angioplasty or stenting, or evidence 
of MI via ECG) were excluded. 
Cancer mortality was recorded regardless of cancer type, as previously described 24. 
Cancer mortality was assessed through semi-annual telephone follow up, death information 
from participant proxies, linkages with the Social Security Death Index (SSDI) as well as the 
National Death Index (NDI). Date of death was confirmed using death certificates, SSDI and/or 
NDI, and cause of death was adjudicated by a committee of experts using all available 
information as recommended by national guidelines 17. 
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Statistical analysis 
HDL-C categories were defined by fasting HDL-C measurement into the following 
categories: ‘very low’ HDL-C (<30 mg/dL), ‘low’ HDL-C (30-<40 mg/dL) and ‘normal’ HDL-
C (≥40 mg/dL) (reference value). To assess the association between the HDL-C categories and 
each outcome, a series of incremental Cox proportional hazards models were employed on 
complete cases: Model 1) adjustment for demographic factors (age, race, sex); Model 2) 
additional adjustment for SES (income level and education level), alcohol consumption, 
physical activity, smoking and BMI; Model 3) additional adjustment for diabetes, estimated 
eGFR, ACR, CRP, statin use, other lipid-lowering medication use, steroid use, and, Model 4) 
additional adjustment for LDL-C and triglycerides. Statistical interactions in the minimally-
adjusted model (Model 1) and final model (Model 4) were used to examine whether the 
associations between HDL-C category and the outcomes varied by sex and race, separately. In 
a separate analysis, Model 4 was used to interrogate the data using multiple imputation with 
chained equations (MICE) 14, 15. For the incremental proportional hazards models, the level of 
significance was set at 0.05, and 0.10 for the interaction analyses 25. A sensitivity analysis 
further explored whether the association between HDL-C category and each outcome changes 
over time, using a joint Wald test of time-varying HDL-C effects in Model 4. Additional 
sensitivity analyses examined continuous HDL-C using restricted cubic splines in Model 4 as 
well as HDL-C quintiles in Models 1 and 4. SAS 9.4 (SAS Institute, Inc.) and R 26 were used 
for all complete case statistical analyses and Stata 14.2 for multiple imputation analyses. 
 
 
RESULTS 
Baseline characteristics 
Of the 21,751 participants that met the complete case inclusion criteria (Supplemental 
Figure 1), 45% of them were male and 39% were black. The mean age was 64.6 (±9.4) years. 
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With respect to HDL-C, 748 (3.4%) participants were in the very low (<30 mg/dL) HDL-C 
category; 4038 (18.6%) in the low (30 - <40 mg/dL), and 16965 (78.0%) were in the normal 
(≥40 mg/dl) category.  
Age, BMI, eGFR, educational status, income, physical activity, smoking, statin use and 
CRP were broadly similar between the categories. Participants in the low and very low HDL 
categories were more likely to be male, white, and to have diabetes than participants with 
normal HDL. HDL category was directly correlated with LDL-C and inversely correlated with 
triglycerides. Baseline characteristics for the population (stratified by HDL-C category) are 
shown in Supplemental Table 1. Detailed number of events and populations for each 
HDL*race and HDL*sex group is presented in Supplemental Table 2. Hazard ratios (HRs) 
describing the association between HDL-C category and risk of all-cause mortality, mortality 
from malignant disease and incident CHD are presented in Supplemental Table 3, and HRs 
describing the association between HDL-C quintile and each outcome of interest by race and 
sex are presented in Supplemental Tables 4 and 5, respectively. Relative hazard of each 
outcome using continuous HDL-C through restricted cubic splines by race and sex are 
presented in Supplementary Figures 2-7. 
  
Relationship between HDL-C category and all-cause-mortality 
The mean person-years follow-up (SD) for all-cause mortality was 7.2 (2.5) years. 
Unadjusted Kaplan-Meier curves showed that, compared with participants in the normal HDL-
C category, all-cause mortality was higher in patients with low, or very low HDL-C (Figure 
1). In Cox proportional hazard models adjusted for age, race, and sex (Model 1), participants 
in the low category of HDL-C had greater risk of death with the HR 1.15 (95% confidence 
interval [CI]: 1.06, 1.25) and the mortality in the very low HDL-C group was greater still 1.48 
(95%CI: 1.28, 1.73), thus demonstrating a monotonic relationship between HDL-C and 
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mortality. Similar results were seen after further adjustment for education level, income level, 
alcohol consumption, physical activity, smoking and BMI (Model 2). Further adjustment 
(Models 3 and 4) attenuated this relationship, as did analysis by MICE (Supplemental Table 
3). There is no evidence that the association between HDL-C category and all-cause mortality 
changes over time (p=0.12).  
In the fully-adjusted model (Model 4), statistically significant differences were observed 
between males and females in the relationship between HDL-C and all-cause mortality (p for 
interaction = 0.08) with numerically larger HR in females (HR 1.31, 95%CI: 0.88, 1.95 for 
HDL-C <30 mg/dL). However, no statistically significant differences between sexes were 
observed when MICE was employed (Table 1). Neither complete case analysis (Model 4) nor 
MICE demonstrated a statistically significant interaction of race with respect to all-cause 
mortality (Table 2). Treating HDL-C continuously, no differences in association with all-cause 
mortality were observed by race (p=0.65; Supplemental Figure 2), but the interaction between 
HDL-C and sex was statistically significant (p<0.01; Supplemental Figure 3). 
 
Relationship between HDL-C and cancer-specific mortality 
The mean person-years follow-up (SD) for cancer-specific mortality was 7.8 (2.8) years. 
Unadjusted Kaplan-Meier curves showed that, compared with participants in the normal HDL-
C category, the rate of cancer mortality was increased in patients with low or very low HDL-
C (Figure 2), which were apparent before 2 years and extend through 10 years of follow up. 
In Cox proportional hazard models adjusted for age, race, and sex (Model 1), participants in 
the low and very low categories of HDL-C had increased risk of cancer-specific mortality - HR 
1.14 (95%CI: 0.99, 1.32) and 1.35 (95%CI: 1.03, 1.77), respectively, and this trend continued 
through models 2, 3 and 4 with gradual effect attenuation, and the effect was not observed with 
MICE (Supplemental Table 3). There is no evidence that the association between HDL-C 
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category and cancer-specific mortality changes over time (p=0.08). In the fully-adjusted model 
(Model 4), using complete case analysis, statistically significant differences were observed 
between males and females in the relationship between HDL-C and cancer-specific mortality 
(p for interaction = 0.014). In females, the very low category of HDL-C was strongly associated 
with the higher risk of cancer (HR 2.31, 95%CI: 1.28, 4.16) compared with men (HR 0.88, 
95%CI: 0.64, 1.21) (Table 1). The difference between cancer mortality between males and 
females was also seen when MICE was employed (p=0.033). Neither complete case analysis 
(Model 4) nor MICE demonstrated a statistically significant interaction of race with respect to 
cancer-specific mortality (Table 2). Examining HDL-C continuously, no differences in 
association with cancer-specific mortality were observed by race (p=0.62; Supplemental 
Figure 4), but the interaction between HDL-C and sex was statistically significant (p<0.01; 
Supplemental Figure 5). 
 
Relationship between HDL-C and incident CHD 
The mean person-years follow-up (SD) for all-cause mortality was 7.0 (2.6) years. 
Unadjusted Kaplan-Meier curves showed that, compared with participants in the normal HDL-
C category, rates of incident CHD were increased in patients with low, or very low HDL-C 
(Figure 3), which were apparent before 2 years and extend through 10 years of follow up. In 
adjusted Cox proportional hazard models (Models 1-4) the observed effect was gradually 
attenuated together with subsequent adjustments (Supplemental Table 3). There is no 
evidence to suggest that the association between HDL-C category and incident CHD varies 
over time (p=0.08). 
Subgroup analysis of the fully-adjusted model (Model 4) using the complete case method 
demonstrated statistically significant effects of sex (Table 1) (p for interaction = 0.008) and 
race (Table 2) (p for interaction = 0.018). The analysis of the relationship between HDL-C and 
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incident CHD in females showed that low HDL-C (30-39.9 mg/dL) was significantly 
associated with a reduced risk of incident CHD (HR 0.57, 95%CI: 0.38, 0.86); conversely, very 
low HDL-C was non-significantly associated with greater risk (HR: 1.57, 95%CI: 0.69, 3.58). 
In males, a different relationship was seen with no effect of low HDL-C (HR 1.04, 95%CI: 
0.85, 1.28), or very low HDL-C (HR: 0.82, 95%CI: 0.55, 1.22) on incident CHD. However, 
these sex differences were not replicated when analysis was performed using MICE (Table 1). 
In whites, participants in the low HDL-C category had a similar incidence of CHD as those in 
the normal (reference) category (HR 1.09, 95%CI: 0.88, 1.35), similar results were seen with 
very low HDL-C (HR 0.92, 95%CI: 0.61, 1.39). Black participants in the low HDL-C category 
were at significant lower risk of incident CHD than those with normal HDL-C (HR 0.63: 
95%CI: 0.46, 0.88), and a similar trend (however not significant) was seen with the very low 
HDL-C group (HR: 0.82, 95%CI: 0.40, 1.68). The significant interaction of race in complete 
case analysis was preserved when MICE analysis was employed (p for interaction = 0.054) 
(Table 2). Significant differences in the association between continuous HDL-C and incidence 
of CHD were observed by both race (p=0.02; Supplemental Figure 6) and sex (p=0.04; 
Supplemental Figure 7). 
 
DISCUSSION 
Our study has demonstrated that HDL-C tertiles were inversely monotonically associated 
with all-cause mortality and cancer-specific mortality in a minimally-adjusted model. A similar 
trend was seen with the relationship between HDL-C and the risk of incident CHD. Analysis 
of racial subgroups revealed that blacks in the ‘low’ and ‘very low’ HDL-C categories 
experienced fewer incident CHD events than those with ‘normal’ HDL-C using both complete 
case and MICE analysis methods. Thus, in this population, our data suggest an ‘HDL paradox’, 
raising the possibility of the existence of an inverted U- or J-curve phenomenon. Subgroup 
 13 
analysis of a fully-adjusted complete case model revealed striking differences between males 
and females. The interaction with sex was significant for all three outcomes, with low HDL-C 
being prognostic of poorer outcomes in females than in males in each case. In particular, in 
females, ‘very low’ HDL was strongly associated with cancer-specific mortality, whereas such 
an effect was not seen in males. This interaction of sex was also observed in MICE analysis, 
however the effect was slightly attenuated (HR goes from 2.31 in complete case to 1.81 in 
MICE). It has long been recognized that population-level HDL-C concentrations are higher in 
adult females than males 27. Thresholds for diagnosing low HDL-C differ between the genders 
(<40 mg/dL in men and <50 mg/dL in women) 28. A similar inverse relationship between HDL-
C and incident cancer has been previously observed in a Chinese cohort study including 17,779 
participants29. Furthermore, a study-level meta-analysis of 625,000 participants demonstrated 
a 36% lower incidence of cancer for every 10 mg/dl increase in HDL-C11. The fact that our 
study complements findings conducted in very different demographic groups and using 
different methodologies is reassuring.  
The results of this study suggest the possibility that HDL-C may be prognostically useful 
in clinical practice beyond the calculation of CVD risk, particularly for women. The poor 
predictive value of HDL-C against CHD among the whole population in this study is consistent 
with results obtained by Mendelian randomization 6 that demonstrate that a causal relationship 
between low HDL-C and MI is unlikely. Our results are consistent with those of Tada et al. 
who conducted an observational study of subjects attending hospital in Japan and whose HDL-
C was measured for any reason 10. Out of a cohort of 43,368 patients, 429 were found to have 
‘extremely low’ HDL-C (<15 mg/L), and mortality was greatest in this group. During the 
median 175 days follow up period, 106 patients in this group died. It is possible that infectious 
diseases are partially responsible for excess mortality in participants with very low HDL-C. 
Our study did not investigate this hypothesis, however recent findings from the Copenhagen 
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City Heart Study indicate that HDL-C <31 mg/dl (almost identical to our ‘very low’ HDL-C 
group) was associated with a HR of 1.75 for infectious disease compared with normal HDL-
C30. This likely reflects the important roles of HDL in immunity and the modulations of HDL 
function during infectious and inflammatory states. HDL particles influence the activity of 
monocytes, macrophages, dendritic cells and T- and B- lymphocytes by altering the cholesterol 
content of lipid rafts31. HDL limits the potential for bacterial lipopolysaccharide to induce 
inflammatory reactions31. However, rapid reductions of HDL-C have been observed during 
acute infections31, and inflammatory states can result in ‘dysfunctional’ HDL which can exert 
pro-inflammatory effects32. Similarly, cytokine release associated with the inflammatory 
response to tumours has been associated with reduced plasma concentrations of HDL-C33. 
Probably the remaining question is whether the relationship between low HDL-C and poor 
outcomes is causal, or whether low HDL-C occurs secondary to another condition, which 
results in morbidity and mortality. Rader and de Goma reviewed the causes of low HDL-C, 
which they divided into artifactual causes (e.g. assay interference by paraproteinemia), primary 
(monogenic) causes (e.g. ApoA-I deficiency or mutation, Tangier disease, heterozygous 
deficiency of ATP-binding cassette transporter A1 [ABCA1], lecithin cholesterol 
acyltransferase [LCAT] deficiency), all of which are uncommon and secondary causes (e.g. 
anabolic androgenic steroids, malignancy and idiosyncratic response to fibrates) 34. In the 
recent study by Tada et al., most cases of low HDL-C were attributable to secondary causes. 
As many as 80 (75%) of the causes of death were either from malignancies, inflammatory 
diseases, or major bleeding, in contrast to a relatively low mortality from CVD (10%) 10. That 
observation is consistent with the finding of this study that low HDL-C was a better predictor 
of all-cause mortality and cancer mortality than it was for incident CHD in complete case 
analysis. However, the results of these studies may not be directly comparable in this respect 
because Tada et al. included in their analysis all patients found to have low HDL-C, whereas 
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in this study, participants with malignancy at baseline were not included in REGARDS and 
patients with CHD at baseline were excluded from the analysis. Thus, in contrast to the study 
by Tada et al, in which most of the very low cases of HDL-C were attributable to secondary 
causes, our study might be considered to focus on the lowest identifiable levels of primary low 
HDL-C. This is reflected in different cut-off points in the categorization of ‘extremely low’ 
HDL: <20 mg/dL in Tada et al, compared with ‘very low’ <30 mg/dl in this study, which 
resulted in 3.5% of our population being included in this group.  
Recent findings suggest that the inverse relationship between HDL-C and triglycerides 
low HDL-C could be attributed to hypertriglyceridemia via augmentation of CETP activity 35. 
Furthermore, the incidence of diabetes was much greater in participants with low and very low 
HDL-C, than those in the ‘normal’ category. The existence of dysfunctional, pro-inflammatory 
HDL-C in diabetes has been described elsewhere36. In this study, the prognostic effects of 
HDL-C in the whole study population were attenuated when the Cox-regression model 2 
correcting for BMI was applied, and further attenuation was seen with Model 3, which corrects 
for diabetes (among other factors). 
Our results suggest a protective effect of HDL-C against cancer. Several lines of 
investigation indicate that such an effect is biologically plausible. Apolipoprotein A-1, the 
constituent lipoprotein of HDL-C has been demonstrated to inhibit tumour development in 
mouse models of ovarian cancer37 and melanoma38 and L-5F, an apolipoprotein mimetic has 
been shown to inhibit tumor angiogenesis39. Other components of the cholesterol efflux / 
reverse cholesterol transport pathway may be involved in the regulation of malignancy. It has 
recently been demonstrated in mouse models that knockout of ATP-binding cassette 
transporters ABCA1 and ABCG1 is protective against melanoma growth and metastasis 40. 
Few populations have a sufficient number of black participants to powerfully assess racial 
differences in the role of HDL and disease risk.  A potentially new finding of this study is the 
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association of lower CHD risk in blacks with HDL-C levels <40 mg/dl, thus apparently 
exhibiting an ‘HDL paradox’. These results, however, should be interpreted with caution, 
especially as the relatively small numbers of participants in the racial subgroups of patients 
with low HDL-C weakened the statistical power of these analyses. Nevertheless, it should be 
noted that the phenomenon was observed after both complete case analysis and MICE, 
reducing the likelihood of an artifactual finding. This is an interesting finding that requires 
further investigation, perhaps in other large cohorts and registries. Racial differences in the 
prognostic utility of HDL-C in CVD risk prediction have been observed before, and a similar 
paradoxical effect of very low HDL-C has been observed in Asians 41. A previous analysis of 
data from black participants in the REGARDS study failed to find an association between low 
HDL-C (defined as <40 mg/dl in men or <50 mg/dl in women) and incident CHD 42. Trends 
indicating similar paradoxically protective effects of ‘low’ or ‘extremely low’ HDL-C were 
seen in other subgroups (all-cause mortality in males and whites; cancer mortality in males; 
and incident CHD in males). None of these latter trends were statistically significant, however 
it is possible that the study was underpowered to detect such effects because of the relatively 
small number of participants in the ‘low’ and ‘extremely low’ HDL-C categories. Differences 
in outcomes in different racial groups may reflect varying prevalence of genetic traits relating 
to HDL-C. Associations of HDL-C, CVD, and genetic variants have been discussed elsewhere 
43, 44 and recently a rare variant of the scavenger receptor B1 has been found to be associated 
with increased HDL-C and an increased risk of CHD 7. Further investigations of this type may 
open the possibility for personalized risk prediction after genetic testing. 
 
Study strengths and limitations  
The large sample size, long period of follow up, and rigorous approach to data collection 
in the REGARDS study make this cohort an extremely useful tool to explore relationships 
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between biomarkers and risks of disease. Nevertheless, such an approach to research has 
several limitations. Observational studies, such as this, cannot demonstrate causality and are 
vulnerable to bias by unknown or unmeasured factors. In this analysis, we have performed both 
complete case and MICE analysis in order to address these difficulties. Complete case analysis 
has the limitation that it can underestimate risks in some subgroups. MICE analysis assumes 
that the probability a variable is missing depends only on observed covariates is based on the 
missing-at-random assumption and is sensitive to departures from this assumption, 
increasingly so with larger amounts of missing data 45. Thus, we have provided both analyses 
for comparison and for completeness.  
In common with many other studies, our analyses are based upon measurement of plasma 
lipids at a single point in time, and could be confounded by undiagnosed disease (particularly 
malignancies) at baseline. LDL-C in this study was calculated by the Friedewald equation, and 
therefore likely represents the sum of LDL-C, lipoprotein (a) and intermediate-density 
lipoprotein cholesterol 19. Greater precision could have been obtained by direct measurement 
of LDL-C, however as the focus of this study was HDL-C, this would be unlikely to affect our 
findings. Other investigators have described a phenomenon of falsely low measurements of 
HDL46, although such artifactual errors are likely to be rare. However, even with this potential 
measurement error the associations discussed were sufficiently strong for detection; and 
importantly we do not know why measurement error would differ between racial groups, and 
as such would not affect the interesting observations with respect to race. In this investigation, 
similar to the results of other investigators 10, there was a very uneven distribution of patients 
across the categories of HDL-C, limiting statistical power, in particular in the very low category 
of HDL, and precluding the study of even lower categories of HDL-C. Since our analysis 
includes all available participants for effect estimation, we are unable to investigate the 
potential confounding of female-specific measures such as menopause or hormone replacement 
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therapy on the relationship between HDL-C and our endpoints. Our study focuses only on 
health outcomes associated with low HDL-C. Health outcomes associated with exceptionally 
high HDL-C will be investigated in future studies. 
 
Conclusions 
Low HDL-C was associated with increased risk for all-cause mortality, cancer mortality, 
and incident CHD in a minimally-adjusted model, however the effect was attenuated in fully-
adjusted model. When complete case analysis was used, for all three outcomes considered, the 
sex-HDL-C interaction was significant with poorer outcomes associated with low HDL-C in 
women than men. Further, the relationship with cancer mortality appears to be specific to 
women. Using both complete case analysis and MICE, we observed the existence of an ‘HDL 
paradox’, whereby low HDL-C associated with lower risk of incident CHD was observed in 
black participants of the REGARDS study. 
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Table 1: Hazard ratios (HRs) describing the association between HDL-C category and risk of all-cause mortality, mortality from malignant disease 
and incident CHD by sex.  
 Complete Case Model 1* Complete Case Model 4* MICE Model 4* 
Female Male Female Male Female Male 
All-cause 
mortality 
HDL 
Strata 
<30 
mg/dL 2.42 (1.64, 3.56) 1.35 (1.15, 1.59) 1.31 (0.88, 1.95) 0.90 (0.81, 1.07) 1.14 (0.83, 1.57) 0.79 (0.56, 1.11) 
30 - < 40 
mg/dL 1.48 (1.27, 1.72) 1.04 (0.94, 1.15) 1.04 (0.89, 1.22) 0.90 (0.81, 1.00) 1.05 (0.91, 1.21) 0.88 (0.75, 1.04) 
>40 
mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p<0.0001 p=0.08 p=0.16 
Cancer-
specific 
mortality 
HDL 
Strata 
<30 
mg/dL 3.31 (1.87, 5.88) 1.13 (0.84, 1.54) 2.31 (1.28, 4.16) 0.88 (0.64, 1.21) 1.81 (1.03, 3.20) 0.44 (0.24, 0.83) 
30 - < 40 
mg/dL 1.33 (1.01, 1.76) 1.07 (0.90, 1.27) 1.07 (0.80, 1.42) 0.97 (0.82, 1.16) 1.09 (0.83, 1.45) 0.86 (0.63, 1.19) 
>40 
mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.003 p=0.014 p=0.033 
Incident 
CHD 
HDL 
Strata 
<30 
mg/dL 2.75 (1.23, 6.18) 1.29 (0.89, 1.88) 1.57 (0.69, 3.58) 0.82 (0.55, 1.22) 1.07 (0.60, 1.90) 0.92 (0.50, 1.70) 
30 - < 40 
mg/dL 0.86 (0.58, 1.28) 1.29 (1.06, 1.57) 0.57 (0.38, 0.86) 1.04 (0.85, 1.28) 0.82 (0.63, 1.07) 1.23 (0.92, 1.63) 
>40 
mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.041 p=0.008 p=0.35 
Abbreviations: HDL-C – high density lipoprotein cholesterol; CHD – coronary heart disease; MICE – Multiple Imputation by Chained Equations 
*Model 1 estimates are adjusted for age, race and sex. Model 4 estimates are additionally adjusted for education level, income level, alcohol consumption, physical activity, current smoking, body 
mass index (BMI), diabetes, albumin-to-creatine ratio (ACR), estimated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering medications (fibrates/niacin), use of steroids, 
high sensitivity C-reactive protein (hsCRP), low density lipoprotein cholesterol (LDL-C), and triglycerides. 
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Table 2. Hazard ratios (HRs) describing the association between HDL-C category and risk of all-cause mortality, mortality from malignant 
disease and incident CHD by race.  
  
Complete Case Model 1* Complete Case Model 4* MICE Model 4* 
Black White Black White Black White 
All-cause 
mortality 
HDL Strata 
<30 mg/dL 1.67 (1.26, 2.22) 1.43 (1.20, 1.70) 1.19 (0.89, 1.59) 0.88 (0.74, 1.06) 0.96 (0.72, 1.28) 0.96 (0.82, 1.12) 
30 - < 40 
mg/dL 1.15 (1.00, 1.32) 1.15 (1.04, 1.27) 0.93 (0.81, 1.07) 0.94 (0.84, 1.05) 0.93 (0.81, 1.07) 0.99 (0.90, 1.10) 
>40 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.64 p=0.21 p=0.61 
Cancer-
specific 
mortality 
HDL Strata 
<30 mg/dL 1.43 (0.82, 2.50) 1.32 (0.97, 1.80) 1.11 (0.63, 1.95) 0.99 (0.72, 1.37) 1.03 (0.58, 1.81) 0.93 (0.66, 1.31) 
30 - < 40 
mg/dL 1.17 (0.91, 1.49) 1.13 (0.95, 1.35) 1.05 (0.82, 1.34) 0.98 (0.81, 1.18) 0.97 (0.72, 1.32) 1.00 (0.84, 1.19) 
>40 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.95 p=0.87 p=0.98 
Incident 
CHD  
HDL Strata 
<30 mg/dL 1.18 (0.58, 2.39) 1.51 (1.02, 2.22) 0.82 (0.40, 1.68) 0.92 (0.61, 1.39) 0.76 (0.50, 1.17) 1.06 (0.83, 1.35) 
30 - < 40 
mg/dL 0.81 (0.59, 1.12) 1.42 (1.16, 1.74) 0.63 (0.46, 0.88) 1.09 (0.88, 1.35) 0.76 (0.58, 0.98) 1.06 (0.91, 1.24) 
>40 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.014 p=0.018 p=0.054 
 
Abbreviations: HDL-C – high-density lipoprotein cholesterol; CHD – coronary heart disease; MICE – Multiple Imputation by Chained Equations. * Model 1 estimates are adjusted for age, race 
and sex. Model 4 estimates are additionally adjusted for education level, income level, alcohol consumption, physical activity, current smoking, body mass index (BMI), diabetes, albumin-to-
creatine ratio (ACR), estimated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering medications (fibrates/niacin), use of steroids,  
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FIGURES’ LEGENDS:  
Figure 1: Unadjusted Kaplan-Meier survival curves with estimates for survival probability for 
all-cause mortality for each of the three HDL-C categories.  
Figure 2: Unadjusted Kaplan-Meier survival curves with estimates for survival probability for 
cancer mortality for each of the three HDL-C categories. 
Figure 3: Unadjusted Kaplan-Meier survival curves with estimates for survival probability for 
incident coronary heart disease for each of the three HDL categories. 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Table 1. Baseline characteristics of participants by HDL category (n = 21751). 
 HDL-C 
< 30 mg/dL 
HDL-C 
30 - <40 mg/dL 
HDL-C 
40 + mg/dL 
Overall n (%) 748 (3.4) 4038 (18.6) 16965 (78.0) 
Continuous Variables, Mean (±SD) 
Age (years) 65.2 (9.0) 64.5 (9.2) 64.6 (9.4) 
Body Mass Index (kg/m2) 30.6 (5.5) 30.5 (5.7) 28.9 (6.2) 
Estimated GFR (CKD-EPI equation) 79.1 (21.8) 83.4 (19.9) 86.4 (19.3) 
LDL-C (mg/dL) 99.4 (33.9) 111.4 (33.1) 116.5 (34.8) 
Triglycerides (mg/dL) 197.0 (82.5) 157.5 (71.6) 114.2 (54.7) 
Categorical Variables, N (Column %) 
Men 633 (84.6) 2854 (70.7) 6282 (37.0) 
Black 179 (23.9) 1283 (31.8) 6997 (41.2) 
Education    
     Less than High School  94 (12.6) 477 (11.8) 1882 (11.1) 
     High School Graduate 172 (23.0) 1041 (25.8) 4374 (25.8) 
     Some College 209 (27.9) 1091 (27.0) 4540 (26.8) 
     College Graduate and More 273 (36.5) 1429 (35.4) 6169 (36.4) 
Income    
     Less than $20k 111 (14.8) 619 (15.3) 2894 (17.1) 
     $20k-$34k 168 (22.5) 945 (23.4) 4092 (24.1) 
     $35k-$74k 273 (36.5) 1330 (32.9) 5095 (30.0) 
     $75k and above 121 (16.2) 698 (17.3) 2858 (16.8) 
     Refused 75 (10.0) 446 (11.1) 2026 (11.9) 
Alcohol Consumption 234 (31.3) 1411 (34.9) 6685 (39.4) 
Physical Activity    
     None 251 (33.6) 1378 (34.1) 5584 (32.9) 
     1-3 times per week 274 (36.6) 1455 (36.0) 6228 (36.7) 
     4 or more times per week 223 (29.8) 1205 (29.8) 5153 (30.4) 
Current Smoking 128 (17.1) 680 (16.8) 2265 (13.4) 
Diabetes 256 (34.2) 1071 (26.5) 2861 (16.9) 
Fibrate Use 49 (6.6) 149 (3.7) 257 (1.5) 
Statin Use 255 (34.1) 1449 (35.9) 5135 (30.3) 
Other Lipid-lowering Medication Use 69 (9.2) 268 (6.6) 511 (3.0) 
Steroid Use 18 (2.4) 112 (2.8) 577 (3.4) 
Urinary Albumin/Creatinine Ratio>30 mg/g 154 (20.6) 680 (16.8) 2221 (13.1) 
C-reactive protein    
     < 1 mg/L 160 (21.4) 898 (22.2) 4714 (27.8) 
     1 - < 3 mg/L 236 (31.6) 1387 (34.4) 5695 (33.6) 
     3+ mg/L 352 (47.1) 1753 (43.4) 6556 (38.6) 
LDL and TG Combination Category    
     LDL <100, TG <150 129 (17.3) 933 (23.1) 4627 (27.3) 
     LDL ≥100, TG <150 120 (16.0) 1307 (32.4) 8934 (52.7) 
     LDL <100, TG ≥150 266 (35.6) 650 (16.1) 1002 (5.9) 
     LDL ≥100, TG ≥150 233 (31.2) 1148 (28.4) 2402 (14.1) 
 
*Abbreviations: HDL-C – high density lipoprotein cholesterol; GFR – glomerular filtration rate; CKD-EPI 
equation – chronic kidney disease – epidemiology collaboration equation; LDL-C – low density lipoprotein 
cholesterol; TG – triglycerides. 
 
Supplementary Table 2. Number of events and populations for each HDL*race and HDL*sex group. 
 
 
Overall Black White Female Male 
Number of 
Events / 
Population 
Crude Incidence Rates 
per 10,000 person-years 
follow-up 
Number of 
Events / 
Population 
Crude Incidence Rates 
per 10,000 person-
years follow-up 
Number of 
Events / 
Population 
Crude Incidence Rates 
per 10,000 person-
years follow-up 
Number of 
Events/Pop
ulation 
Crude Incidence Rates 
per 10,000 person-
years follow-up 
Number of 
Events / 
Population 
Crude Incidence Rates 
per 10,000 person-
years follow-up 
All-
cause 
mortality 
HDL 
Strata 
<30 
mg/dL 192/748 357.2 (311.7, 409.4) 50/179 421.6 (321.7, 553.5) 142/569 339.0 (289.5, 397.0) 26/115 353.8 (242.7, 515.9) 166/633 357.8 (309.1, 414.1) 
30 - < 
40 
mg/dL 
761/4038 260.7 (243.4, 279.4) 252/1283 282.7 (250.8, 318.6) 509/2755 251.1 (230.8, 273.3) 187/1184 229.6 (200.0, 263.8) 574/2854 272.8 (251.9, 295.4) 
>40 
mg/dL 2557/16965 209.5 (201.8, 217.6) 1114/6997 229.5 (216.7, 243.0) 1443/9968 196.4 (186.7, 206.5) 1293/10683 169.7 (160.9, 178.9) 1264/6282 275.9 (261.5, 291.1) 
Overall Event 3510/21751 224.2 (217.1, 231.5) 1416/8459 241.4 (229.5, 254.0) 2094/13292 213.8 (205.1, 222.9) 1506/11982 177.0 (168.5, 185.9) 2004/9769 280.3 (268.6, 292.5) 
Cancer-
specific 
mortality 
HDL 
Strata 
<30 
mg/dL 58/748 100.5 (77.8, 129.8) 13/179 103.9 (60.6, 178.2) 45/569 99.6 (74.5, 133.2) 12/115 145.1 (82.3, 255.9) 46/633 92.4 (69.3, 123.2) 
30 - < 
40 
mg/dL 
255/4038 80.6 (71.4, 91.0) 81/1283 84.0 (67.8, 104.2) 174/2755 79.1 (68.2, 91.7) 56/1184 60.7 (46.7, 78.9) 199/2854 87.3 (76.0, 100.2) 
>40 
mg/dL 843/16965 63.6 (59.5, 68.0) 348/6997 66.1 (59.5, 73.3) 495/9968 61.9 (56.7, 67.6) 426/10683 47.1 (42.6, 52.0) 417/6282 84.2 (76.6, 92.6) 
Overall Event 1156/21751 68.0 (64.2, 72.0) 442/8459 69.5 (63.4, 76.3) 714/13292 67.1 (62.4, 72.1) 494/11982 53.3 (48.8, 58.1) 662/9769 85.7 (79.4, 92.4) 
Incident 
CHD 
HDL 
Strata 
<30 
mg/dL 36/488 177.1 (144.2, 217.5) 8/134 138.0 (84.5, 225.5) 28/354 188.5 (150.3, 236.3) 6/82 154.2 (85.0, 279.7) 30/406 180.8 (145.2, 225.0) 
30 - < 
40 
mg/dL 
182/3075 119.7 (107.6, 133.2) 44/1026 94.3 (76.0, 117.0) 138/2049 131.1 (116.0, 148.2) 26/966 71.0 (54.8, 91.9) 156/2109 139.1 (123.8, 156.4) 
>40 
mg/dL 604/14192 81.7 (76.7, 86.9) 268/5932 84.2 (76.4, 92.9) 336/8260 80.0 (73.7, 86.8) 312/9305 59.4 (54.2, 65.2) 292/4887 119.1 (109.4, 129.6) 
Overall Event 822/17755 91.9 (87.2, 96.8) 320/7092 86.8 (79.5, 94.8) 502/10663 94.9 (89.0, 101.3) 344/10353 61.4 (56.3, 66.9) 478/7402 128.9 (120.7, 137.6) 
 
*Crude incidence rates and 95% CI were estimated through modified Poisson regression (Poisson regression with robust standard error estimation) 
Supplementary Table 3. Hazard ratios (HRs) describing the association between HDL-C category and risk of all-cause mortality, mortality from malignant 
disease and incident CHD.  
 
 HDL Strata Model 1 
Complete 
Cases 
Model 2 
Complete 
Cases 
Model 3 
Complete 
Cases 
Model 4 
Complete 
Cases 
Model 4 
MICE 
All-cause 
mortality 
<30 mg/dL 1.48  
(1.28, 1.73) 
1.25 
(1.08, 1.46) 
1.07 
(0.92, 1.25) 
0.99 
(0.84, 1.16) 
1.01 
(0.87, 1.18) 
30 - < 40 mg/dL 1.15 
(1.06, 1.25) 
1.05 
(0.96, 1.14) 
0.98 
(0.90, 1.07) 
0.95 
(0.87, 1.04) 
0.99 
(0.90, 1.08) 
> 40 mg/dL 1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
Cancer-specific 
mortality 
<30 mg/dL 1.35 
(1.03, 1.77) 
1.19 
(0.91, 1.57) 
1.10 
(0.83, 1.45) 
1.02 
(0.76, 1.36) 
0.95 
(0.69, 1.30) 
30 - < 40 mg/dL 1.14 
(0.99, 1.32) 
1.07 
(0.92, 1.24) 
1.03 
(0.89, 1.20) 
1.00 
(0.86, 1.17) 
0.96 
(0.82, 1.13) 
> 40 mg/dL 1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
Incident CHD <30 mg/dL 1.39 
(0.99, 1.96) 
1.10 
(0.78, 1.56) 
0.95 
(0.67, 1.34) 
0.90 
(0.63, 1.30) 
0.83 
(0.66, 1.04) 
30 - < 40 mg/dL 1.19 
(1.00, 1.41) 
1.03 
(0.86, 1.22) 
0.97 
(0.81, 1.15) 
0.93 
(0.78, 1.12) 
0.89 
(0.77, 1.03) 
> 40 mg/dL 1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
1.00 
(ref) 
 
*Abbreviations: HDL-C – high density lipoprotein cholesterol; CHD – coronary heart disease; MICE, Multiple Imputation with Chained Equations. Model 1 adjusts for age, race, and sex. 
Model 2 additionally adjusts for education level, income level, alcohol consumption, physical activity, current smoking, and body mass index (BMI); Model 3 additionally adjusts for diabetes, 
albumin-to-creatine ratio (ACR), estimated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering medications (fibrates/niacin), high sensitivity C-reactive protein (hsCRP), 
and steroid use; Model 4 additionally adjusts for LDL-C and triglycerides. 
 
 
 
 
Supplemental Table 4: Hazard ratios (HRs) describing the association between HDL-C quintile and risk of all-cause mortality, mortality from malignant 
disease and incident CHD by race.  
 
Complete Case Model 1* Complete Case Model 4* MICE Model 4* 
Black White Black White Black White 
All-cause 
mortality 
HDL 
Quintile 
1st 
5-38 mg/dL 1.37 (1.16, 1.63) 1.39 (1.20, 1.60) 0.97 (0.82, 1.16) 0.89 (0.76, 1.04) 0.96 (0.81, 1.15) 0.98 (0.85, 1.11) 
2nd 
39-45 mg/dL 1.16 (0.98, 1.38) 1.25 (1.07, 1.45) 0.93 (0.78, 1.11) 0.96 (0.82, 1.12) 0.92 (0.76, 1.10) 1.04 (0.91, 1.19) 
3rd 
46-53 mg/dL 1.19 (1.01, 1.40) 1.17 (1.01, 1.36) 1.06 (0.90, 1.26) 0.97 (0.83, 1.13) 0.99 (0.83, 1.19) 1.01 (0.88, 1.15) 
4th 
54-64 mg/dL 1.06 (0.90, 1.25) 1.06 (0.91, 1.24) 1.05 (0.89, 1.24) 0.95 (0.81, 1.11) 1.02 (0.85, 1.24) 0.96 (0.84, 1.10) 
5th 
65-166 
mg/dL 
1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.94 p=0.66 p=0.79 
Cancer-
specific 
mortality 
HDL 
Quintile 
1st 
5-38 mg/dL 1.46 (1.06, 2.01) 1.28 (1.01, 1.64) 1.19 (0.86, 1.66) 1.01 (0.77, 1.31) 1.26 (0.91, 1.74) 0.95 (0.75, 1.22) 
2nd 
39-45 mg/dL 1.46 (1.08, 1.98) 1.10 (0.85, 1.42) 1.27 (0.93, 1.73) 0.98 (0.75, 1.27) 1.15 (0.83, 1.61) 1.04 (0.82, 1.32) 
3rd 
46-53 mg/dL 1.34 (0.99, 1.80) 1.08 (0.84, 1.39) 1.26 (0.93, 1.71) 0.99 (0.76, 1.28) 1.17 (0.83, 1.61) 0.99 (0.78, 1.25) 
4th 
54-64 mg/dL 1.14 (0.84, 1.55) 1.01 (0.78, 1.31) 1.10 (0.81, 1.50) 0.95 (0.73, 1.24) 1.15 (0.81, 1.63) 0.95 (0.75, 1.21) 
5th 
65-166 
mg/dL 
1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.67 p=0.72 p=0.76 
Incident 
CHD 
HDL 
Quintile 
1st 
5-38 mg/dL 1.22 (0.81, 1.83) 1.84 (1.35, 2.49) 0.77 (0.50, 1.17) 1.03 (0.74, 1.44) 0.81 (0.59 (1.11) 1.30 (1.03, 1.63) 
2nd 
39-45 mg/dL 1.59 (1.10, 2.29) 1.62 (1.18, 2.21) 1.12 (0.77, 1.62) 1.09 (0.78, 1.51) 0.99 (0.71, 1.37) 1.28 (1.01, 1.60) 
3rd 1.36 (0.95, 1.96) 1.56 (1.14, 2.12) 1.07 (0.74, 1.55) 1.14 (0.83, 1.57) 1.01 (0.73., 1.40) 1.28 (1.01, 1.60) 
46-53 mg/dL 
4th 
54-64 mg/dL 1.63 (1.15, 2.31) 1.06 (0.75, 1.49) 1.48 (1.04, 2.10) 0.89 (0.63, 1.25) 1.43 (1.01, 2.02) 1.01 (0.79, 1.29) 
5th 
65-166 
mg/dL 
1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.009 p=0.013 p=0.005 
Abbreviations: HDL-C – high density lipoprotein cholesterol; CHD – coronary heart disease; MICE – Multiple Imputation by Chained Equations. *Model 1 estimates are adjusted for age, race 
and sex. Model 4 estimates are additionally adjusted for education level, income level, alcohol consumption, physical activity, current smoking, body mass index (BMI), diabetes, albumin-to-
creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering medications (fibrates/niacin), use of steroids, high sensitivity C-reactive protein 
(hsCRP), low density lipoprotein cholesterol (LDL-C), and triglycerides. 
  
Supplemental Table 5: Hazard ratios (HRs) describing the association between HDL-C quintile and risk of all-cause mortality, mortality from malignant 
disease and incident CHD by sex.  
 
Complete Case Model 1* Complete Case Model 4* MICE Model 4* 
Female Male Female Male Female Male 
All-cause 
mortality 
HDL 
Quintile 
1st 
5-38 mg/dL 1.87 (1.57, 2.24) 1.02 (0.87, 1.20) 1.12 (0.93, 1.35) 0.74 (0.62, 0.88) 1.12 (0.96, 1.30) 0.74 (0.61, 0.90) 
2nd 
39-45 mg/dL 1.42 (1.21, 1.66) 0.91 (0.77, 1.08) 1.09 (0.92, 1.28) 0.76 (0.64, 0.91) 1.14 (1.00, 1.30) 0.74 (0.61, 0.90) 
3rd 
46-53 mg/dL 1.38 (1.19, 1.59) 0.87 (0.74, 1.04) 1.16 (1.00, 1.35) 0.80 (0.67, 0.95) 1.09 (0.96, 1.23) 0.80 (0.66, 0.97) 
4th 
54-64 mg/dL 1.12 (0.97, 1.29) 0.89 (0.74, 1.06) 1.05 (0.90, 1.21) 0.85 (0.71, 1.02) 0.97 (0.85, 1.09) 0.98 (0.80, 1.19) 
5th 
65-166 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p<0.0001 p=0.003 p=0.001 
Cancer-
specific 
mortality 
HDL 
Quintile 
1st 
5-38 mg/dL 1.95 (1.43, 2.65) 0.94 (0.71, 1.23) 1.46 (1.05, 2.03) 0.79 (0.59, 1.06) 1.34 (1.01, 1.78) 0.61 (0.43, 0.87) 
2nd 
39-45 mg/dL 1.74 (1.33, 2.27) 0.80 (0.60, 1.07) 1.51 (1.14, 1.99) 0.74 (0.55, 1.00) 1.47 (1.15, 1.88) 0.56 (0.40, 0.78) 
3rd 
46-53 mg/dL 1.38 (1.07, 1.79) 0.84 (0.63, 1.13) 1.26 (0.97, 1.65) 0.82 (0.61, 1.11) 1.21 (0.96, 1.53) 0.68 (0.49, 0.96) 
4th 
54-64 mg/dL 1.09 (0.84, 1.41) 0.89 (0.65, 1.22) 1.04 (0.80, 1.35) 0.86 (0.63, 1.18) 1.03 (0.82, 1.29) 0.91 (0.64, 1.29) 
5th 
65-166 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p<0.0002 p=0.002 p=0.002 
Incident 
CHD 
HDL 
Quintile 
1st 
5-38 mg/dL 1.33 (0.84, 2.11) 1.32 (0.94, 1.86) 0.71 (0.44, 1.15) 0.84 (0.58, 1.20) 1.17 (0.88, 1.55) 0.92 (0.64, 1.31) 
2nd 
39-45 mg/dL 1.85 (1.32, 2.60) 1.21 (0.85, 1.73) 1.22 (0.86, 1.73) 0.89 (0.62, 1.28) 1.46 (1.16, 1.85) 0.72 (0.51, 1.01) 
3rd 
46-53 mg/dL 1.93 (1.42, 2.62) 0.98 (0.68, 1.43) 1.43 (1.04, 1.95) 0.79 (0.54, 1.15) 1.44 (1.15, 1.81) 0.74 (0.52, 1.04) 
4th 
54-64 mg/dL 1.57 (1.15, 2.13) 0.93 (0.63, 1.39) 1.33 (0.98, 1.82) 0.85 (0.57, 1.27) 1.29 (1.03, 1.61) 0.80 (0.56, 1.15) 
5th 
65-166 mg/dL 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
p for interaction p=0.024 p=0.022 p=0.22 
Abbreviations: HDL-C – high density lipoprotein cholesterol; CHD – coronary heart disease; MICE – Multiple Imputation by Chained Equations. * Model 1 estimates are adjusted for age, race 
and sex. Model 4 estimates are additionally adjusted for education level, income level, alcohol consumption, physical activity, current smoking, body mass index (BMI), diabetes, albumin-to-
creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), use of statins, use of other lipid-lowering medications (fibrates/niacin), use of steroids, high sensitivity C-reactive protein 
(hsCRP), low density lipoprotein cholesterol (LDL-C), and triglycerides. 
 
 
 
  
Supplementary Figure 1. The final flow-chart of the sample size.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2: Adjusted all-cause mortality ratios using HDL-C restricted cubic splines by race, relative to white participants with HDL-C of 40 
mg/dL.  
 
  
Supplemental Figure 3: Adjusted all-cause mortality ratios using HDL-C restricted cubic splines by sex, relative to female participants with HDL-C of 40 
mg/dL.  
 
  
Supplemental Figure 4: Adjusted cancer mortality ratios using HDL-C restricted cubic splines by race, relative to white participants with HDL-C of 40 
mg/dL.  
  
Supplemental Figure 5: Adjusted cancer mortality ratios using HDL-C restricted cubic splines by sex, relative to female participants with HDL-C of 40 
mg/dL.  
 
  
Supplemental Figure 6: Adjusted incident CHD ratios using HDL-C restricted cubic splines by race, relative to white participants with HDL-C of 40 mg/dL.  
  
Supplemental Figure 7: Adjusted incident CHD ratios using HDL-C restricted cubic splines by sex, relative to white participants with HDL-C of 40 mg/dL. 
 
 
